Management of sickle cell disease from childhood through adulthood

Blood Reviews

Volumn 27, Issue 6, 2013, Pages 279-287

  Kanter, Julie ^a   Kruse Jarres, Rebecca ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adult; Haematology; Paediatric; Sickle cell disease

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN S; HYDROMORPHONE; HYDROXYUREA; IBUPROFEN; KETOROLAC; MORPHINE; PLACEBO;

ACUTE CHEST SYNDROME; ADULTHOOD; ARTICLE; ASTHMA; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CHILDHOOD; CHRONIC PAIN; CLINICAL FEATURE; DISEASE EXACERBATION; DOPPLER ECHOGRAPHY; DRUG EFFICACY; EXCHANGE BLOOD TRANSFUSION; GROWTH RETARDATION; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; IRON OVERLOAD; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; NEUTROPENIA; NEWBORN SCREENING; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN; PATHOPHYSIOLOGY; POINT MUTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SYMPTOM; TRANSITION TO ADULT CARE; VASCULAR DISEASE; VASOOCCLUSIVE DISEASE; VASOOCCLUSIVE EPISODE;

ADULT; HAEMATOLOGY; PAEDIATRIC; SICKLE CELL DISEASE;

ADOLESCENT; ADULT; AGE FACTORS; ANEMIA, SICKLE CELL; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84887608596     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2013.09.001     Document Type: Article

References (77)

1. Schnog J.B., Duits A.J., Muskiet F.A., ten Cate H., Rojer R.A., Brandjes D.P. Sickle cell disease; a general overview. Neth J Med 2004, 62:364-374.
2. Claster S., Vichinsky E.P. Managing sickle cell disease. BMJ 2003, 327:1151-1155.
3. Modell B., Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008, 86:480-487.
4. Weatherall D.J. The inherited diseases of hemoglobin are an emerging global health burden. Blood 2010, 115:4331-4336.
5. Buchanan G., Vichinsky E., Krishnamurti L., Shenoy S. Severe sickle cell disease - pathophysiology and therapy. Biol Blood Marrow Transplant 2010, 16:S64-S67.
6. Therrell B.L., Hannon W.H. National evaluation of US newborn screening system components. Ment Retard Dev Disabil Res Rev 2006, 12:236-245.
7. Brousseau D.C., Panepinto J.A., Nimmer M., Hoffmann R.G. The number of people with sickle-cell disease in the United States: national and state estimates. Am J Hematol 2010, 85:77-78.
8. Hassell K.L. Population estimates of sickle cell disease in the U.S. Am J Prev Med 2010, 38:S512-S521.
9. Quinn C.T., Rogers Z.R., McCavit T.L., Buchanan G.R. Improved survival of children and adolescents with sickle cell disease. Blood 2010, 115:3447-3452.
10. Gaston M.H., Verter J.I., Woods G., Pegelow C., Kelleher J., Presbury G., et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986, 314:1593-1599.
11. Streetly A., Latinovic R., Hall K., Henthorn J. Implementation of universal newborn bloodspot screening for sickle cell disease and other clinically significant haemoglobinopathies in England: screening results for 2005-7. J Clin Pathol 2009, 62:26-30.
12. Yanni E., Grosse S.D., Yang Q., Olney R.S. Trends in pediatric sickle cell disease-related mortality in the United States, 1983-2002. J Pediatr 2009, 154:541-545.
13. Adamkiewicz T.V., Silk B.J., Howgate J., Baughman W., Strayhorn G., Sullivan K., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008, 121:562-569.
14. Grosse S.D., Odame I., Atrash H.K., Amendah D.D., Piel F.B., Williams T.N. Sickle cell disease in Africa: a neglected cause of early childhood mortality. Am J Prev Med 2011, 41:S398-S405.
15. Brown M. Managing the acutely ill adult with sickle cell disease. Br J Nurs 2012, 21(90-2):5-6.
16. Odièvre M.H., Verger E., Silva-Pinto A.C., Elion J. Pathophysiological insights in sickle cell disease. Indian J Med Res 2011, 134:532-537.
17. Looney M.R., Matthay M.A. Neutrophil sandwiches injure the microcirculation. Nat Med 2009, 15:364-366.
18. Novartis AG Iron Health Alliance Sickle cell disease Available at, [accessed July 18, 2013]. http://www.ironhealthalliance.com/disease-states/sickle-cell-disease.jsp.
19. Al-Saqladi A.W., Cipolotti R., Fijnvandraat K., Brabin B.J. Growth and nutritional status of children with homozygous sickle cell disease. Ann Trop Paediatr 2008, 28:165-189.
20. Anim S.O., Strunk R.C., DeBaun M.R. Asthma morbidity and treatment in children with sickle cell disease. Expert Rev Respir Med 2011, 5:635-645.
21. Ellison A.M., Shaw K. Management of vasoocclusive pain events in sickle cell disease. Pediatr Emerg Care 2007, 23:832-838. quiz 8-41.
22. Benton T.D., Ifeagwu J.A., Smith-Whitley K. Anxiety and depression in children and adolescents with sickle cell disease. Curr Psychiatry Rep 2007, 9:114-121.
23. Quinn C.T., Rogers Z.R., Buchanan G.R. Survival of children with sickle cell disease. Blood 2004, 103:4023-4027.
24. Telfer P., Coen P., Chakravorty S., Wilkey O., Evans J., Newell H., et al. Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London. Haematologica 2007, 92:905-912.
25. Strouse J.J., Jordan L.C., Lanzkron S., Casella J.F. The excess burden of stroke in hospitalized adults with sickle cell disease. Am J Hematol 2009, 84:548-552.
26. Wang W.C. The pathophysiology, prevention, and treatment of stroke in sickle cell disease. Curr Opin Hematol 2007, 14:191-197.
27. DeBaun M.R., Sarnaik S.A., Rodeghier M.J., Minniti C.P., Howard T.H., Iyer R.V., et al. Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood 2012, 119:3684-3690.
28. DeBaun M.R., Schatz J., Siegel M.J., Koby M., Craft S., Resar L., et al. Cognitive screening examinations for silent cerebral infarcts in sickle cell disease. Neurology 1998, 50:1678-1682.
29. Adams R.J., McKie V.C., Hsu L., Files B., Vichinsky E., Pegelow C., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 1998, 339:5-11.
30. Armstrong-Wells J., Grimes B., Sidney S., Kronish D., Shiboski S.C., Adams R.J., et al. Utilization of TCD screening for primary stroke prevention in children with sickle cell disease. Neurology 2009, 72:1316-1321.
31. Dennis-Antwi J.A., Dyson S.M., Ohene-Frempong K. Healthcare provision for sickle cell disease: challenges for the African context. Divers. Health Soc. Care 2008, 5:241-254.
32. Morris C.R. Asthma management: reinventing the wheel in sickle cell disease. Am J Hematol 2009, 84:234-241.
33. Boyd J.H., Macklin E.A., Strunk R.C., DeBaun M.R. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica 2007, 92:1115-1118.
34. Ballas S.K., Lusardi M. Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance. Am J Hematol 2005, 79:17-25.
35. Manci E.A., Culberson D.E., Yang Y.M., Gardner T.M., Powell R., Haynes J., et al. Causes of death in sickle cell disease: an autopsy study. Br J Haematol 2003, 123:359-365.
36. Vichinsky E.P., Styles L.A., Colangelo L.H., Wright E.C., Castro O., Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 1997, 89:1787-1792.
37. Platt O.S., Thorington B.D., Brambilla D.J., Milner P.F., Rosse W.F., Vichinsky E., et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991, 325:11-16.
38. McClish D.K., Levenson J.L., Penberthy L.T., Roseff S.D., Bovbjerg V.E., Roberts J.D., et al. Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. J Womens Health (Larchmt) 2006, 15:146-154.
39. Strouse J.J., Lanzkron S., Urrutia V. The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol 2011, 4:597-606.
40. Glassberg J. Evidence-based management of sickle cell disease in the emergency department. Emerg Med Pract 2011, 13:1-20. [quiz].
41. de Montalembert M. Management of sickle cell disease. BMJ 2008, 337:a1397.
42. Pegelow C.H., Adams R.J., McKie V., Abboud M., Berman B., Miller S.T., et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 1995, 126:896-899.
43. Vichinsky E. New therapies in sickle cell disease. Lancet 2002, 360:629-631.
44. Strouse J.J., Heeney M.M. Hydroxyurea for the treatment of sickle cell disease: efficacy, barriers, toxicity, and management in children. Pediatr Blood Cancer 2012, 59:365-371.
45. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332:1317-1322.
46. Ferster A., Vermylen C., Cornu G., Buyse M., Corazza F., Devalck C., et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996, 88:1960-1964.
47. Alvarez O., Miller S.T., Wang W.C., Luo Z., McCarville M.B., Schwartz G.J., et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer 2012, 59:668-674.
48. McGann P.T., Flanagan J.M., Howard T.A., Dertinger S.D., He J., Kulharya A.S., et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer 2012, 59:254-257.
49. Thornburg C.D., Files B.A., Luo Z., Miller S.T., Kalpatthi R., Iyer R., et al. Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood 2012, 120:4304-4310. [quiz 448].
50. Styles L.A., Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr 1994, 125:909-911.
51. Brittenham G.M. Iron-chelating therapy for transfusional iron overload. N Engl J Med 2011, 364:146-156.
52. Meerpohl J.J., Antes G., Rücker G., Fleeman N., Niemeyer C., Bassler D. Deferasirox for managing transfusional iron overload in people with sickle cell disease. Cochrane Database Syst Rev 2010, CD007477.
53. Scothorn D.J., Price C., Schwartz D., Terrill C., Buchanan G.R., Shurney W., et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr 2002, 140:348-354.
54. Hulbert M.L., McKinstry R.C., Lacey J.L., Moran C.J., Panepinto J.A., Thompson A.A., et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011, 117:772-779.
55. Ware R.E., Helms R.W., Investigators S.W. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012, 119:3925-3932.
56. de Montalembert M. Current strategies for the management of children with sickle cell disease. Expert Rev Hematol 2009, 2:455-463.
57. Thompson A.A. Primary prophylaxis in sickle cell disease: is it feasible? Is it effective?. Hematology Am Soc Hematol Educ Program 2011, 2011:434-439.
58. Khoury R., Abboud M.R. Stem-cell transplantation in children and adults with sickle cell disease: an update. Expert Rev Hematol 2011, 4:343-351.
59. Oringanje C., Nemecek E., Oniyangi O. Hematopoietic stem cell transplantation for children with sickle cell disease. Cochrane Database Syst Rev 2009, CD007001.
60. Solomon L.R. Treatment and prevention of pain due to vaso-occlusive crises in adults with sickle cell disease: an educational void. Blood 2008, 111:997-1003.
61. Aygun B., Padmanabhan S., Paley C., Chandrasekaran V. Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions. Transfusion 2002, 42:37-43.
62. Taylor L.E., Stotts N.A., Humphreys J., Treadwell M.J., Miaskowski C. A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. J Pain Symptom Manage 2010, 40:416-435.
63. Wright K., Adeosum O. Barriers to effective pain management in sickle cell disease. Br J Nurs 2009, 18:158-161.
64. Telfair J., Haque A., Etienne M., Tang S., Strasser S. Rural/urban differences in access to and utilization of services among people in Alabama with sickle cell disease. Public Health Rep 2003, 118:27-36.
65. Haque A., Telfair J. Socioeconomic distress and health status: the urban-rural dichotomy of services utilization for people with sickle cell disorder in North Carolina. J Rural Health 2000, 16:43-55.
66. Kelly A.M., Kratz B., Bielski M., Rinehart P.M. Implementing transitions for youth with complex chronic conditions using the medical home model. Pediatrics 2002, 110:1322-1327.
67. Prabhakar H., Haywood C., Molokie R. Sickle cell disease in the United States: looking back and forward at 100years of progress in management and survival. Am J Hematol 2010, 85:346-353.
68. Treadwell M., Telfair J., Gibson R.W., Johnson S., Osunkwo I. Transition from pediatric to adult care in sickle cell disease: establishing evidence-based practice and directions for research. Am J Hematol 2011, 86:116-120.
69. Brousseau D.C., Owens P.L., Mosso A.L., Panepinto J.A., Steiner C.A. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010, 303:1288-1294.
70. Wojciechowski E.A., Hurtig A., Dorn L. A natural history study of adolescents and young adults with sickle cell disease as they transfer to adult care: a need for case management services. J Pediatr Nurs 2002, 17:18-27.
71. Doulton D.M. From cradle to commencement: transitioning pediatric sickle cell disease patients to adult providers. J Pediatr Oncol Nurs 2010, 27:119-123.
72. Howard J., Woodhead T., Musumadi L., Martell A., Inusa B.P. Moving young people with sickle cell disease from paediatric to adult services. Br J Hosp Med (Lond) 2010, 71:310-314.
73. Frenette P.S., Atweh G.F. Sickle cell disease: old discoveries, new concepts, and future promise. J Clin Invest 2007, 117:850-858.
74. Sadelain M. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol 2006, 13:142-148.
75. Hebbel R.P., Vercellotti G., Nath K.A. A systems biology consideration of the vasculopathy of sickle cell anemia: the need for multi-modality chemo-prophylaxsis. Cardiovasc Hematol Disord Drug Targets 2009, 9:271-292.
76. Tailor A., Cooper D., Granger D.N. Platelet-vessel wall interactions in the microcirculation. Microcirculation 2005, 12:275-285.
77. Gladwin M.T., Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med 2008, 359:2254-2265.